Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Asparaginase induced hemorrhagic pancreatitis is a rare but serious development occurring in less than 0.5% of patients treated with this drug. Severe pancreatitis with progressive abdominal distention, toxemia, hypotension and respiratory insufficiency occurred in an 18-year-old patient with acute lymphoblastic leukemia following treatment with asparaginase. There was a dramatic response to high flow peritoneal lavage with rapid recovery within 24 hours from a moribund state. The subsequent development of a pseudocyst, with progressive increase in size and development of obstructive symptoms, required surgical decompression. Transgastric cystogastrostomy was successfully carried out.
D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000150:complications / Q000628:therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D010181:Pancreatic Cyst / Q000150:complications* / Q000209:etiology / Q000601:surgery; D010195:Pancreatitis / Q000139:chemically induced* / Q000150:complications / Q000628:therapy; D010530:Peritoneal Dialysis / Q000009:adverse effects
D001215:Asparaginase